Zymeworks, Inc. (ZYME)
28.87
+0.02
(+0.07%)
USD |
NASDAQ |
Oct 28, 16:00
28.87
0.00 (0.00%)
After-Hours: 16:52
Zymeworks Enterprise Value : 2.074B for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 2.074B |
| October 26, 2026 | 2.040B |
| October 23, 2026 | 2.029B |
| October 22, 2026 | 2.045B |
| October 21, 2026 | 2.021B |
| October 20, 2026 | 1.934B |
| October 19, 2026 | 1.836B |
| October 16, 2026 | 1.799B |
| October 15, 2026 | 1.851B |
| October 14, 2026 | 1.780B |
| October 13, 2026 | 1.802B |
| October 12, 2026 | 1.821B |
| October 09, 2026 | 1.854B |
| October 08, 2026 | 1.816B |
| October 07, 2026 | 1.907B |
| October 06, 2026 | 1.844B |
| October 05, 2026 | 1.884B |
| October 02, 2026 | 1.808B |
| October 01, 2026 | 1.866B |
| September 30, 2026 | 1.904B |
| September 29, 2026 | 1.955B |
| September 28, 2026 | 1.950B |
| September 25, 2026 | 1.906B |
| September 24, 2026 | 1.927B |
| September 23, 2026 | 1.977B |
| Date | Value |
|---|---|
| September 22, 2026 | 1.982B |
| September 21, 2026 | 1.927B |
| September 18, 2026 | 1.910B |
| September 17, 2026 | 1.975B |
| September 16, 2026 | 1.886B |
| September 15, 2026 | 1.873B |
| September 14, 2026 | 1.930B |
| September 11, 2026 | 1.886B |
| September 10, 2026 | 1.900B |
| September 09, 2026 | 1.952B |
| September 08, 2026 | 2.021B |
| September 04, 2026 | 2.099B |
| September 03, 2026 | 2.150B |
| September 02, 2026 | 2.232B |
| September 01, 2026 | 2.133B |
| August 31, 2026 | 2.114B |
| August 28, 2026 | 2.032B |
| August 27, 2026 | 2.086B |
| August 26, 2026 | 2.107B |
| August 25, 2026 | 1.975B |
| August 24, 2026 | 2.068B |
| August 21, 2026 | 2.061B |
| August 20, 2026 | 1.910B |
| August 19, 2026 | 1.956B |
| August 18, 2026 | 1.874B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 570.37B |
| Aprea Therapeutics, Inc. | -34.15M |
| ACADIA Pharmaceuticals, Inc. | 2.589B |
| Alnylam Pharmaceuticals, Inc. | 30.01B |
| Anika Therapeutics, Inc. | 272.57M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -45.02M |
| Revenue (Quarterly) | 4.59M |
| Total Expenses (Quarterly) | 49.61M |
| EPS Diluted (Quarterly) | -0.6168 |
| Gross Profit Margin (Quarterly) | 57.43% |
| Profit Margin (Quarterly) | -980.8% |
| Earnings Yield | -6.98% |
| Normalized Earnings Yield | -6.968 |